Like a Rolling Stone:Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity Disorder and Autistic Spectrum Disorder by Damkier, Per
Syddansk Universitet
Like a Rolling Stone
Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity
Disorder and Autistic Spectrum Disorder
Damkier, Per
Published in:
American Journal of Epidemiology
DOI:
10.1093/aje/kwy202
Publication date:
2018
Document version
Peer reviewed version
Citation for pulished version (APA):
Damkier, P. (2018). Like a Rolling Stone: Prenatal Exposure to Acetaminophen and Risk for Attention Deficit
Hyperactivity Disorder and Autistic Spectrum Disorder. American Journal of Epidemiology. DOI:
10.1093/aje/kwy202
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Nov. 2018
Letter to the Editor 
Like a Rolling Stone: Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity 
Disorder and Autistic Spectrum Disorder. 
 
Per Damkier 
Professor, MD PhD 
Department of Clinical Biochemistry and Pharmacology 
Odense University Hospital 
Department of Clinical research 
University of Southern Denmark 
Odense, Denmark 
 
 
 
 
 
 
 
 
 
 © The Author(s) 2018. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public 
Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/aje/advance-article-abstract/doi/10.1093/aje/kw
y202/5091522 by D
anish R
egions user on 10 O
ctober 2018
To the Editor 
Like a Rolling Stone: Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity 
Disorder and Autistic Spectrum Disorder. 
I read with interest the systematic review and metaanalysis by Marsawa et al. on attention deficit 
hyperactivity disorder (ADHD), autistic spectrum disorder (ASD) and “hyperactivity symptoms” following in 
utero exposure to acetaminophen (1). I strongly applaud the authors call for more robust and validated 
outcome tools to study childhood neurodevelopment following in utero exposure to drugs. While perhaps 
not a complete unknown, the issue of acetaminophen during pregnancy and childhood neurodevelopment 
remain controversial and contested (2–5). An important contribution to our understanding of this subject 
was provided in a recent study (6). Ystrom and colleagues reported comparable weak signals for the risk of 
ADHD following maternal in utero exposure and paternal preconception acetaminophen exposure. This 
very important point, which should force the epidemiologically minded community to revisit the issue of 
causality and confounding on this matter, is not discussed by the authors of the present systematic review 
(1). 
I challenge the decision to subject the studies selected for the systematic review to a meta-analysis, much 
less a meta-regression, approach. The authors state accurately, in their paragraph on study limitations, that 
assessments of the principal outcome variables as well as exposure are very heterogenous and subject to 
bias and confounding in the underlying studies. This describes a situation where the characteristics of the 
underlying data should discourage a meta-analysis approach for observational studies (7), hence the quite 
predictable and revealing I2 values of 72, 14 and 92% for ADHD, ASD and “hyperactivity symptoms”, 
respectively. The apparent low heterogeneity for ASD is unsurprising given that this diagnosis carries a 
strong degree of heritability of 83-90% (8,9).  
I find it inconsequential to 1) list a seemingly insurmountable obstacle of limitations, not least assessment 
of the primary outcome parameter of interest, which mitigate the findings of the underlying studies 2) state 
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appropriate substantial reservations with respect to interpretations of study findings and call for more 
research on the validity of the principal outcome parameters 3) yet perform a meta-analysis which forces 
these fundamentally incomparable data through the same rabbit hole. I believe the meta-analysis approach 
is inappropriate given the data at hand and the application thereof is more likely to have produced 
potential harmful statistical noise rather than contributed to a meaningful elucidation of the scientific 
questions posed. 
Finally, the authors cite “…recent alarming evidence on the teratogenicity of acetaminophen…” in the 
section on implications for policy and practice. This is an exceptional and unnecessarily opinioned 
statement with substantial implications to healthcare professionals and pregnant women in pain. I am 
unaware of such “…recent alarming evidence on the teratogenicity of acetaminophen...” relevant to the 
clinical use of acetaminophen in pregnant women. The statement is not referenced and is not supported by 
any “evidence” that the authors bring forward in their paper. It is a necessity that this explicit and - I 
assume - deliberate choice of words be substantiated, appropriately referenced and justified by the 
authors.  
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